Navegando por Palavras-chave "disease burden"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Historical epidemiology of hepatitis C virus (HCV) in selected countries
    (Wiley-Blackwell, 2014-05-01) Bruggmann, P.; Berg, T.; Ovrehus, A. L. H.; Moreno, C.; Brandao Mello, C. E.; Roudot-Thoraval, F.; Marinho, R. T.; Sherman, M.; Ryder, S. D.; Sperl, J.; Akarca, U.; Balik, I.; Bihl, F.; Bilodeau, M.; Blasco, A. J.; Buti, M.; Calinas, F.; Calleja, J. L.; Cheinquer, H.; Christensen, P. B.; Clausen, M.; Coelho, H. S. M.; Cornberg, M.; Cramp, M. E.; Dore, G. J.; Doss, W.; Duberg, A. S.; El-Sayed, M. H.; Ergor, G.; Esmat, G.; Estes, C.; Falconer, K.; Felix, J.; Ferraz, Maria Lucia Gomes [UNIFESP]; Ferreira, Paulo Roberto [UNIFESP]; Frankova, S.; Garcia-Samaniego, J.; Gerstoft, J.; Giria, J. A.; Goncales, F. L.; Gower, E.; Gschwantler, M.; Guimaraes Pessoa, M.; Hezode, C.; Hofer, H.; Husa, P.; Idilman, R.; Kaberg, M.; Kaita, K. D. E.; Kautz, A.; Kaymakoglu, S.; Krajden, M.; Krarup, H.; Laleman, W.; Lavanchy, D.; Lazaro, P.; Marotta, P.; Mauss, S.; Mendes Correa, M. C.; Muellhaupt, B.; Myers, R. P.; Negro, F.; Nemecek, V.; Ormeci, N.; Parkes, J.; Peltekian, K. M.; Ramji, A.; Razavi, H.; Reis, N.; Roberts, S. K.; Rosenberg, W. M.; Sarmento-Castro, R.; Sarrazin, C.; Semela, D.; Shiha, G. E.; Sievert, W.; Starkel, P.; Stauber, R. E.; Thompson, A. J.; Urbanek, P.; van Thiel, I.; Van Vlierberghe, H.; Vandijck, D.; Vogel, W.; Waked, I.; Wedemeyer, H.; Weis, N.; Wiegand, J.; Yosry, A.; Zekry, A.; Van Damme, P.; Aleman, S.; Hindman, S. J.; Arud Ctr Addict Med; Univ Leipzig; Odense Univ Hosp; Univ Libre Brussels; Universidade Federal do Rio de Janeiro (UFRJ); Hop Henri Mondor; Hosp Santa Maria; Univ Toronto; Nottingham Univ Hosp NHS Trust; Biomed Res Unit; Inst Clin & Expt Med; Ege Univ; Ankara Univ; Osped Cantonale; Univ Montreal; Adv Tech Hlth Serv Res TAISS; Hosp Valle de Hebron; Hosp Santo Antonio Capuchos; Hosp Puerta Hierro; Univ Fed Rio Grande do Sul; Region Hosp Hovedstaden; Hannover Med Sch; German Liver Fdn; Univ Plymouth; Univ New S Wales; Cairo Univ; Orebro Univ Hosp; Univ Orebro; Ain Shams Univ; Dokuz Eylul Univ; Ctr Dis Anal CDA; Karolinska Inst; Exigo Consultores; Universidade Federal de São Paulo (UNIFESP); Hosp Carlos III; Univ Copenhagen; Direccao Geral Saude; Universidade Estadual de Campinas (UNICAMP); Wilhelminenspital Stadt Wien; Universidade de São Paulo (USP); Med Univ Vienna; Masaryk Univ; Univ Manitoba; Hlth Sci Ctr; European Liver Patients Assoc; Istanbul Univ; Univ British Columbia; Aalborg Univ Hosp; Katholieke Univ Leuven; Univ Western Ontario; Univ Dusseldorf; Univ Zurich Hosp; Univ Calgary; Univ Hosp; Natl Inst Publ Hlth; Univ Southhampton; Dalhousie Univ; Capital Dist Hlth Author; Assembleia Republ; Alfred Hosp; Monash Univ; UCL; Ctr Hosp Porto; JW Goethe Univ Hosp; Cantonal Hosp St Gallen; Egyptian Liver Res Inst & Hosp ELRIAH; Monash Hlth; Catholic Univ Louvain; Med Univ Graz; St Vincents Hosp; Univ Melbourne; Charles Univ Prague; Cent Mil Hosp; Deutsch Leberhilfe eV; Ghent Univ Hosp; Univ Ghent; Hasselt Univ; Med Univ Innsbruck; Natl Liver Inst; Copenhagen Univ Hosp; Univ Antwerp; Karolinska Univ Hosp
    Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. for some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. the largest viremic populations were in Egypt, with 6358000 cases in 2008 and Brazil with 2106000 cases in 2007. the age distribution of cases differed between countries. in most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
    (Wiley-Blackwell, 2014-05-01) Razavi, H.; Waked, I.; Sarrazin, C.; Myers, R. P.; Idilman, R.; Calinas, F.; Vogel, W.; Mendes Correa, M. C.; Hezode, C.; Lazaro, P.; Akarca, U.; Aleman, S.; Balik, I.; Berg, T.; Bihl, F.; Bilodeau, M.; Blasco, A. J.; Brandao Mello, C. E.; Bruggmann, P.; Buti, M.; Calleja, J. L.; Cheinquer, H.; Christensen, P. B.; Clausen, M.; Coelho, H. S. M.; Cramp, M. E.; Dore, G. J.; Doss, W.; Duberg, A. S.; El-Sayed, M. H.; Ergor, G.; Esmat, G.; Falconer, K.; Felix, J.; Ferraz, Maria Lucia Gomes [UNIFESP]; Ferreira, Paulo Roberto [UNIFESP]; Frankova, S.; Garcia-Samaniego, J.; Gerstoft, J.; Giria, J. A.; Goncales, F. L.; Gower, E.; Gschwantler, M.; Guimaraes Pessoa, M.; Hindman, S. J.; Hofer, H.; Husa, P.; Kaberg, M.; Kaita, K. D. E.; Kautz, A.; Kaymakoglu, S.; Krajden, M.; Krarup, H.; Laleman, W.; Lavanchy, D.; Marinho, R. T.; Marotta, P.; Mauss, S.; Moreno, C.; Murphy, K.; Negro, F.; Nemecek, V.; Ormeci, N.; Ovrehus, A. L. H.; Parkes, J.; Pasini, K.; Peltekian, K. M.; Ramji, A.; Reis, N.; Roberts, S. K.; Rosenberg, W. M.; Roudot-Thoraval, F.; Ryder, S. D.; Sarmento-Castro, R.; Semela, D.; Sherman, M.; Shiha, G. E.; Sievert, W.; Sperl, J.; Starkel, P.; Stauber, R. E.; Thompson, A. J.; Urbanek, P.; Van Damme, P.; van Thiel, I.; Van Vlierberghe, H.; Vandijck, D.; Wedemeyer, H.; Weis, N.; Wiegand, J.; Yosry, A.; Zekry, A.; Cornberg, M.; Muellhaupt, B.; Estes, C.; Ctr Dis Anal; Natl Liver Inst; JW Goethe Univ Hosp; Univ Calgary; Ankara Univ; Hosp Santo Antonio Capuchos; Med Univ Innsbruck; Universidade de São Paulo (USP); Hop Henri Mondor; Adv Tech Hlth Serv Res TAISS; Ege Univ; Karolinska Inst; Karolinska Univ Hosp; Univ Leipzig; Osped Cantonale; Univ Montreal; Fed Univ State Rio de Janeiro; Arud Ctr Addict Med; Hosp Valle de Hebron; Hosp Puerta Hierro; Univ Fed Rio Grande do Sul; Odense Univ Hosp; Reg Hosp Hovedstaden; Universidade Federal do Rio de Janeiro (UFRJ); Univ Plymouth; Univ New S Wales; Cairo Univ; Orebro Univ Hosp; Univ Orebro; Ain Shams Univ; Dokuz Eylul Univ; Exigo Consultores; Universidade Federal de São Paulo (UNIFESP); Inst Clin & Expt Med; Hosp Carlos III; Univ Copenhagen; Direccao Geral Saude; Universidade Estadual de Campinas (UNICAMP); Wilhelminenspital Stadt Wien; Med Univ Vienna; Masaryk Univ; Univ Manitoba; Hlth Sci Ctr; European Liver Patients Assoc; Istanbul Univ; Univ British Columbia; Aalborg Univ Hosp; Katholieke Univ Leuven; Hosp Santa Maria; Univ Western Ontario; Univ Dusseldorf; Univ Libre Brussels; Univ Hosp; Natl Inst Publ Hlth; Univ Southhampton; Dalhousie Univ & Hepatol Serv; Assembleia Republ; Alfred Hosp; Monash Univ; UCL; Nottingham Univ Hosp NHS Trust; Biomed Res Unit; Ctr Hosp Porto; Cantonal Hosp St Gallen; Univ Toronto; Egyptian Liver Res Inst & Hosp; Monash Hlth; Catholic Univ Louvain; Med Univ Graz; St Vincents Hosp; Univ Melbourne; Charles Univ Prague; Cent Mil Hosp; Univ Antwerp; Deutsch Leberhilfe eV; Ghent Univ Hosp; Univ Ghent; Hannover Med Sch; Copenhagen Univ Hosp; Univ Zurich Hosp
    The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. in addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Strategies to manage hepatitis C virus (HCV) disease burden
    (Wiley-Blackwell, 2014-05-01) Wedemeyer, H.; Duberg, A. S.; Buti, M.; Rosenberg, W. M.; Frankova, S.; Esmat, G.; Ormeci, N.; Van Vlierberghe, H.; Gschwantler, M.; Akarca, U.; Aleman, S.; Balik, I.; Berg, T.; Bihl, F.; Bilodeau, M.; Blasco, A. J.; Brandao Mello, C. E.; Bruggmann, P.; Calinas, F.; Calleja, J. L.; Cheinquer, H.; Christensen, P. B.; Clausen, M.; Coelho, H. S. M.; Cornberg, M.; Cramp, M. E.; Dore, G. J.; Doss, W.; El-Sayed, M. H.; Ergor, G.; Estes, C.; Falconer, K.; Felix, J.; Ferraz, Maria Lucia Gomes [UNIFESP]; Ferreira, Paulo Roberto [UNIFESP]; Garcia-Samaniego, J.; Gerstoft, J.; Giria, J. A.; Goncales, F. L.; Guimaraes Pessoa, M.; Hezode, C.; Hindman, S. J.; Hofer, H.; Husa, P.; Idilman, R.; Kaberg, M.; Kaita, K. D. E.; Kautz, A.; Kaymakoglu, S.; Krajden, M.; Krarup, H.; Laleman, W.; Lavanchy, D.; Lazaro, P.; Marinho, R. T.; Marotta, P.; Mauss, S.; Mendes Correa, M. C.; Moreno, C.; Muellhaupt, B.; Myers, R. P.; Nemecek, V.; Ovrehus, A. L. H.; Parkes, J.; Peltekian, K. M.; Ramji, A.; Razavi, H.; Reis, N.; Roberts, S. K.; Roudot-Thoraval, F.; Ryder, S. D.; Sarmento-Castro, R.; Sarrazin, C.; Semela, D.; Sherman, M.; Shiha, G. E.; Sperl, J.; Starkel, P.; Stauber, R. E.; Thompson, A. J.; Urbanek, P.; Van Damme, P.; van Thiel, I.; Vandijck, D.; Vogel, W.; Waked, I.; Weis, N.; Wiegand, J.; Yosry, A.; Zekry, A.; Negro, F.; Sievert, W.; Gower, E.; Hannover Med Sch; German Liver Fdn; Orebro Univ Hosp; Univ Orebro; Hosp Valle de Hebron; UCL; Inst Clin & Expt Med; Cairo Univ; Ankara Univ; Ghent Univ Hosp; Wilhelminenspital Stadt Wien; Ege Univ; Karolinska Inst; Karolinska Univ Hosp; Univ Leipzig; Osped Cantonale; Univ Montreal; Adv Tech Hlth Serv Res TAISS; Fed Univ State Rio de Janeiro; Arud Ctr Addict Med; Hosp Santo Antonio Capuchos; Hosp Puerta Hierro; Univ Fed Rio Grande do Sul; Odense Univ Hosp; Region Hosp Hovedstaden; Universidade Federal do Rio de Janeiro (UFRJ); Univ Plymouth; Univ New S Wales; Ain Shams Univ; Dokuz Eylul Univ; Ctr Dis Anal CDA; Exigo Consultores; Universidade Federal de São Paulo (UNIFESP); Hosp Carlos III; Univ Copenhagen; Direccao Geral Saude; Universidade Estadual de Campinas (UNICAMP); Universidade de São Paulo (USP); Hop Henri Mondor; Med Univ Vienna; Masaryk Univ; Univ Manitoba; Hlth Sci Ctr; European Liver Patients Assoc; Istanbul Univ; Univ British Columbia; Aalborg Univ Hosp; Katholieke Univ Leuven; Univ Western Ontario; Univ Dusseldorf; Univ Libre Brussels; Univ Zurich Hosp; Univ Calgary; Natl Inst Publ Hlth; Univ Southhampton; Dalhousie Univ & Hepatol Serv; Assembleia Republ; Alfred Hosp; Monash Univ; Nottingham Univ Hosp NHS Trust; Biomed Res Unit; Ctr Hosp Porto; JW Goethe Univ Hosp; Cantonal Hosp St Gallen; Univ Toronto; Egyptian Liver Res Inst & Hosp ELRIAH; Catholic Univ Louvain; Med Univ Graz; St Vincents Hosp; Univ Melbourne; Charles Univ Prague; Cent Mil Hosp; Univ Antwerp; Deutsch Leberhilfe eV; Univ Ghent; Hasselt Univ; Med Univ Innsbruck; Natl Liver Inst; Copenhagen Univ Hosp; Univ Hosp; Monash Hlth
    The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. the largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.